ID27933A - Gabungan protein farnesiltransferase dan inhibitor hmg-coa reduktase serta penggunaannya untuk mengobati kanker - Google Patents
Gabungan protein farnesiltransferase dan inhibitor hmg-coa reduktase serta penggunaannya untuk mengobati kankerInfo
- Publication number
- ID27933A ID27933A IDW20002583A ID20002583A ID27933A ID 27933 A ID27933 A ID 27933A ID W20002583 A IDW20002583 A ID W20002583A ID 20002583 A ID20002583 A ID 20002583A ID 27933 A ID27933 A ID 27933A
- Authority
- ID
- Indonesia
- Prior art keywords
- reducture
- farnesiltrans
- ferase
- hmg
- coa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8520298P | 1998-05-12 | 1998-05-12 | |
| US9225398P | 1998-07-10 | 1998-07-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ID27933A true ID27933A (id) | 2001-05-03 |
Family
ID=26772425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IDW20002583A ID27933A (id) | 1998-05-12 | 1999-05-10 | Gabungan protein farnesiltransferase dan inhibitor hmg-coa reduktase serta penggunaannya untuk mengobati kanker |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6492410B1 (fr) |
| EP (1) | EP1077949A2 (fr) |
| JP (1) | JP2002514628A (fr) |
| KR (1) | KR20010043529A (fr) |
| CN (1) | CN1171874C (fr) |
| AP (1) | AP2000001984A0 (fr) |
| AU (1) | AU758891B2 (fr) |
| BG (1) | BG105003A (fr) |
| BR (1) | BR9911785A (fr) |
| CA (1) | CA2331295A1 (fr) |
| EA (1) | EA003860B1 (fr) |
| EE (1) | EE200000660A (fr) |
| GE (1) | GEP20032996B (fr) |
| HK (1) | HK1038355A1 (fr) |
| HR (1) | HRP20000771A2 (fr) |
| HU (1) | HUP0102322A3 (fr) |
| ID (1) | ID27933A (fr) |
| IL (1) | IL139502A0 (fr) |
| IS (1) | IS5713A (fr) |
| NO (1) | NO20005680L (fr) |
| NZ (1) | NZ508357A (fr) |
| OA (1) | OA11551A (fr) |
| PL (1) | PL344662A1 (fr) |
| SK (1) | SK16742000A3 (fr) |
| WO (1) | WO1999058505A2 (fr) |
| YU (1) | YU68900A (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000047196A2 (fr) * | 1999-02-11 | 2000-08-17 | Hollis-Eden Pharmaceuticals, Inc. | Méthodes pour traiter des infections virales |
| US6455734B1 (en) * | 2000-08-09 | 2002-09-24 | Magnesium Diagnostics, Inc. | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| US20020010128A1 (en) * | 2000-04-13 | 2002-01-24 | Parks Thomas P. | Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism |
| US20020132781A1 (en) * | 2000-10-06 | 2002-09-19 | George Kindness | Combination and method of treatment of cancer utilizing a COX-2 inhibitor and A 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitor |
| GB0220885D0 (en) * | 2002-09-09 | 2002-10-16 | Novartis Ag | Organic compounds |
| WO2005042710A1 (fr) * | 2003-10-28 | 2005-05-12 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Utilisation de statines pour detruire des cellules b transformees par virus d'epstein-barr (veb) |
| SG166829A1 (en) * | 2005-11-08 | 2010-12-29 | Ranbaxy Lab Ltd | Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
| KR100930365B1 (ko) * | 2006-11-09 | 2009-12-08 | 덕성여자대학교 산학협력단 | 심바스타틴을 유효성분으로 함유하는 유방암 치료용 약학적조성물 |
| US20080119444A1 (en) * | 2006-11-16 | 2008-05-22 | Steven Lehrer | Methods and compositions for the treatment of cancer |
| US10722465B1 (en) | 2017-12-08 | 2020-07-28 | Quicksilber Scientific, Inc. | Transparent colloidal vitamin supplement |
| US11344497B1 (en) | 2017-12-08 | 2022-05-31 | Quicksilver Scientific, Inc. | Mitochondrial performance enhancement nanoemulsion |
| US11291702B1 (en) | 2019-04-15 | 2022-04-05 | Quicksilver Scientific, Inc. | Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK523288A (da) * | 1987-10-06 | 1989-04-07 | Hoffmann La Roche | Aminosyrederivater |
| NL9002031A (nl) | 1990-09-14 | 1992-04-01 | Voskuilen Woudenberg Bv | Inrichting voor het bewerken van een uitwendig buisoppervlak. |
| US5571792A (en) | 1994-06-30 | 1996-11-05 | Warner-Lambert Company | Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase |
| WO1997000894A1 (fr) * | 1995-06-22 | 1997-01-09 | Novo Nordisk A/S | Composes presentant des proprietes de liberation de l'hormone de croissance |
| DK0833847T3 (da) | 1995-06-22 | 2003-12-29 | Biogen Inc | Krystaller af fregmenter af CD40-ligand og deres anvendelse |
| UA57081C2 (uk) * | 1997-06-16 | 2003-06-16 | Пфайзер Продактс Інк. | Фармацевтична композиція для лікування раку або доброякісних проліферативних хвороб у ссавців, спосіб лікування, фармацевтична композиція для інгібування ненормального росту клітин у ссавців та спосіб інгібування |
-
1999
- 1999-05-10 EE EEP200000660A patent/EE200000660A/xx unknown
- 1999-05-10 IL IL13950299A patent/IL139502A0/xx unknown
- 1999-05-10 ID IDW20002583A patent/ID27933A/id unknown
- 1999-05-10 GE GEAP19995670A patent/GEP20032996B/en unknown
- 1999-05-10 JP JP2000548309A patent/JP2002514628A/ja active Pending
- 1999-05-10 WO PCT/US1999/010188 patent/WO1999058505A2/fr not_active Application Discontinuation
- 1999-05-10 YU YU68900A patent/YU68900A/sh unknown
- 1999-05-10 CN CNB99807649XA patent/CN1171874C/zh not_active Expired - Fee Related
- 1999-05-10 EP EP99922898A patent/EP1077949A2/fr not_active Withdrawn
- 1999-05-10 EA EA200001164A patent/EA003860B1/ru not_active IP Right Cessation
- 1999-05-10 AP APAP/P/2000/001984A patent/AP2000001984A0/en unknown
- 1999-05-10 US US09/674,818 patent/US6492410B1/en not_active Expired - Fee Related
- 1999-05-10 KR KR1020007012632A patent/KR20010043529A/ko not_active Application Discontinuation
- 1999-05-10 PL PL99344662A patent/PL344662A1/xx not_active Application Discontinuation
- 1999-05-10 SK SK1674-2000A patent/SK16742000A3/sk unknown
- 1999-05-10 OA OA1200000310A patent/OA11551A/en unknown
- 1999-05-10 BR BR9911785-1A patent/BR9911785A/pt not_active IP Right Cessation
- 1999-05-10 NZ NZ508357A patent/NZ508357A/xx unknown
- 1999-05-10 CA CA002331295A patent/CA2331295A1/fr not_active Abandoned
- 1999-05-10 HU HU0102322A patent/HUP0102322A3/hu unknown
- 1999-05-10 AU AU39792/99A patent/AU758891B2/en not_active Ceased
-
2000
- 2000-11-10 IS IS5713A patent/IS5713A/is unknown
- 2000-11-10 NO NO20005680A patent/NO20005680L/no not_active Application Discontinuation
- 2000-11-13 HR HR20000771A patent/HRP20000771A2/hr not_active Application Discontinuation
- 2000-11-29 BG BG105003A patent/BG105003A/xx unknown
-
2001
- 2001-12-27 HK HK01109123A patent/HK1038355A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0102322A2 (hu) | 2001-11-28 |
| CA2331295A1 (fr) | 1999-11-18 |
| EA200001164A1 (ru) | 2001-06-25 |
| EP1077949A2 (fr) | 2001-02-28 |
| YU68900A (sh) | 2002-12-10 |
| AP2000001984A0 (en) | 2000-12-31 |
| EE200000660A (et) | 2002-04-15 |
| IL139502A0 (en) | 2001-11-25 |
| NZ508357A (en) | 2002-09-27 |
| IS5713A (is) | 2000-11-10 |
| PL344662A1 (en) | 2001-11-19 |
| US6492410B1 (en) | 2002-12-10 |
| BG105003A (en) | 2001-07-31 |
| HUP0102322A3 (en) | 2001-12-28 |
| JP2002514628A (ja) | 2002-05-21 |
| HRP20000771A2 (en) | 2001-06-30 |
| SK16742000A3 (sk) | 2001-07-10 |
| CN1306515A (zh) | 2001-08-01 |
| AU758891B2 (en) | 2003-04-03 |
| HK1038355A1 (en) | 2002-03-15 |
| AU3979299A (en) | 1999-11-29 |
| GEP20032996B (en) | 2003-06-25 |
| EA003860B1 (ru) | 2003-10-30 |
| NO20005680D0 (no) | 2000-11-10 |
| WO1999058505A3 (fr) | 2000-01-06 |
| OA11551A (en) | 2004-05-24 |
| NO20005680L (no) | 2001-01-10 |
| CN1171874C (zh) | 2004-10-20 |
| BR9911785A (pt) | 2001-04-03 |
| KR20010043529A (ko) | 2001-05-25 |
| WO1999058505A2 (fr) | 1999-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2018023I2 (el) | Ενωσεις υποκατεστημενου κυκλοπεντανιου και κυκλοπεντενιου χρησιμες ως αναστολεις νευραμινιδασης | |
| ID27394A (id) | Kombinasi farmasi yang mengandung inhibitor cox-2 dan inhibitor inos | |
| EE200000488A (et) | Fosfolipaasensüümide inhibiitorid ja farmatseutilised kompositsioonid | |
| ID18416A (id) | Inhibitor metaloprotease diheterosiklik | |
| NO20004550D0 (no) | Enzyminhibitorer | |
| EE200100659A (et) | Diaminotiasoolid ja nende kasutamine proteiinikinaaside pärssimiseks | |
| NO20004220D0 (no) | Inhibitorer av fosfolipaseenzymer | |
| NO20000487D0 (no) | Substituerte quinazolinderivater og anvendelse derav som tyrosin kinase inhibitorer | |
| DZ3223A1 (fr) | Inhibiteurs de tyrosine kinases | |
| IS5547A (is) | Forlyf fyrir tálma við aspartílprótínkljúfum | |
| EE200100373A (et) | Bensoheterotsüklid ja nende kasutamine MEK inhibiitoritena | |
| EE200200715A (et) | Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena | |
| BR1100403A (pt) | Composto e composição farmacêutica de inibidores de cox-2 | |
| ID30322A (id) | HETEROSIKLIK YANG MENGANDUNG INHIBITOR BIFENIL aP2 DAN METODANYA | |
| ID30139A (id) | Kompleks dari inhibitor ras-farnesiltransferase dan sulfobutileter-7- -siklodekstrin atau 2-hidroksipropil- -siklodekstrin dan metodanya | |
| EE9900600A (et) | Uued amidinoderivaadid ja nende kasutamine trombiini inhibiitoritena | |
| EE9900006A (et) | Uued amidinoderivaadid ja nende kasutamine trombiini inhibiitoritena | |
| ID22956A (id) | Sintesa disulfida dan polisulfida organik | |
| ID27933A (id) | Gabungan protein farnesiltransferase dan inhibitor hmg-coa reduktase serta penggunaannya untuk mengobati kanker | |
| ID27192A (id) | Sulfonamida trisiklik dan turunannya sebagai inhibitor metaloproteinase matriks | |
| NO20001979D0 (no) | Anvendelse av inhibitorer av renin-angiotensin-systemet | |
| PT927183E (pt) | Inibidores espirociclicos de metaloproteases | |
| EE200300249A (et) | GABA agonistide ja aldoosreduktaasi inhibiitoritekombinatsioon | |
| ID22650A (id) | Penggunaan penghambat-penghambat lipase usus lambung | |
| PT1047450E (pt) | Combinacoes inibidor ace - inibidor mmp |